נגישות
menu      
חיפוש מתקדם

Gupta, M.- Department of Biotechnology, School of Biotechnology and Biosciences, Lovely Professional University, Phagwara, Punjab, India; Department of Biotechnology, Maharishi Markandeshwar University, Mullana, Haryana, India.  
Saxena, S. - Department of Biotechnology, Thapar Institute of Engineering and Technology, Patiala, Punjab, India.

Heart-related diseases such as high blood pressure, myocardial infarction and ischaemic heart diseases are primarily caused by accumulation of fibrin in the walls of the blood vessels resulting in the formation of a haemostatic plug or a clot. In such conditions, thrombolytic therapy is considered as the gold standard to obtain recanalisation of blood flow in partially occluded veins and arteries. Thrombolytic drugs like streptokinase, alteplase, reteplase and tenecteplase are intravenously administered to recanalise the occluded arteries and veins. Streptokinase is the oldest and most commonly used fibrinolytic agent worldwide. The isolation of streptokinase from β-haemolytic streptococci of Lancefield groups A, C and G is considered as a landmark discovery in thrombolytic therapy which has paved the way for finding novel thrombolytic molecules from microbial resources. Over the years, many novel thrombolytic agents have been discovered from a variety of microbial entities like bacteria, actinomycetes, fungi and algae. This chapter reviews important fibrinolytic agents isolated from various microbial sources.

פותח על ידי קלירמאש פתרונות בע"מ -
הספר "אוצר וולקני"
אודות
תנאי שימוש
Microbial clot busters: An overview of source, production, properties and fibrinolytic activity

Gupta, M.- Department of Biotechnology, School of Biotechnology and Biosciences, Lovely Professional University, Phagwara, Punjab, India; Department of Biotechnology, Maharishi Markandeshwar University, Mullana, Haryana, India.  
Saxena, S. - Department of Biotechnology, Thapar Institute of Engineering and Technology, Patiala, Punjab, India.

Microbial clot busters: An overview of source, production, properties and fibrinolytic activity

Heart-related diseases such as high blood pressure, myocardial infarction and ischaemic heart diseases are primarily caused by accumulation of fibrin in the walls of the blood vessels resulting in the formation of a haemostatic plug or a clot. In such conditions, thrombolytic therapy is considered as the gold standard to obtain recanalisation of blood flow in partially occluded veins and arteries. Thrombolytic drugs like streptokinase, alteplase, reteplase and tenecteplase are intravenously administered to recanalise the occluded arteries and veins. Streptokinase is the oldest and most commonly used fibrinolytic agent worldwide. The isolation of streptokinase from β-haemolytic streptococci of Lancefield groups A, C and G is considered as a landmark discovery in thrombolytic therapy which has paved the way for finding novel thrombolytic molecules from microbial resources. Over the years, many novel thrombolytic agents have been discovered from a variety of microbial entities like bacteria, actinomycetes, fungi and algae. This chapter reviews important fibrinolytic agents isolated from various microbial sources.

Scientific Publication
You may also be interested in